Document is current
Any future updates will be listed below
-
Authors
Dickerson, David M.
Kalia, Hemant
Vorenkamp, Kevin E.
Slavin, Konstantin V.
Hagedorn, Jonathan M.
Gunnarsson, Candace
Keuffel, Eric L. https://orcid.org/0000-0001-5350-2272
Epstein, Andrew J.
Stultz, Mark
Crosby, Nathan D. https://orcid.org/0000-0001-6181-0806
-
Funding
Funding for this research was provided by:
SPR Therapeutics
- License Information
-
More Information
Article History
Received: 2 October 2024
Accepted: 18 October 2024
First Online: 26 November 2024
Declarations
:
: Dave Dickerson is a consultant to Abbott, Vertos, Biotronik, and SPR Therapeutics, and his institution has received research funding from Abbott. Hemant Kalia is a consultant to Abbott, Averitas Pharma, Nalu, and SPR Therapeutics, and serves on advisory boards for Curonix and Abbott. Kevin Vorenkamp reports no disclosures. Konstantin Slavin and/or his institution have received consulting income, research and educational grants from Medtronic, Abbott, Boston Scientific, ATI, MSEI and Neuros; he has minor ownership or ownership options in Neuramodix, Thermaquil, and Higgs Boson. Jonathan Hagedorn reports no disclosures. Candace Gunnarsson, Eric Keuffel, and Andy Epstein are consultants to SPR Therapeutics. Mark Stultz and Nathan Crosby are employees of SPR Therapeutics and hold stock options in SPR Therapeutics.
: The study was conducted in accordance with relevant sections of the U.S. Code of Federal Regulations, the Declaration of Helsinki, and International Conference on Harmonization guidelines for good clinical practice. The analysis of anonymized data from Centers for Medicare & Medicaid Services (CMS) files was exempted from review by the WIRB-Copernicus Group IRB under 45 CFR 46.104(d)[]. The study also included anonymized outcomes data reviewed retrospectively under a waiver of consent in an IRB-approved study (WIRB-Copernicus Group IRB). No patient-identifying information is included in this manuscript.
